Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

A Study of PRO95780 in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer (APM4074g)

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: bevacizumab
Drug: carboplatin
Drug: paclitaxel
Drug: PRO95780
Drug: placebo

First Posted Date: 2007-05-31

Last Posted Date: 2017-05-18

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 128

Registration Number: NCT00480831

Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Abraxane
Drug: Bevacizumab
Drug: Carboplatin

First Posted Date: 2007-05-28

Last Posted Date: 2015-02-18

Lead Sponsor: Duke University

Target Recruit Count: 41

Registration Number: NCT00479674

Locations: 🇺🇸
Presbyterian Health Care, Charlotte, North Carolina, United States
🇺🇸
Northeast Oncology Associates, Concord, North Carolina, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

and more 1 locations

Irinotecan and Carboplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Carboplatin
Drug: irinotecan hydrochloride

First Posted Date: 2007-05-07

Last Posted Date: 2012-07-27

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 50

Registration Number: NCT00469898

Locations: 🇺🇸
Tennessee Cancer Specialists, Knoxville, Tennessee, United States
🇺🇸
Owensboro Medical Health System, Owensboro, Kentucky, United States
🇨🇦
British Columbia Cancer Agency - Vancouver Cancer Centre, Vancouver, Canada

and more 5 locations

Enzastaurin, Carboplatin, and Gemcitabine With or Without Bevacizumab in Treating Patients With Recurrent, Stage IIIB, or Stage IV Non-Small Cell Lung Cancer

Phase 2

Withdrawn

Conditions: Lung Cancer

First Posted Date: 2007-05-07

Last Posted Date: 2015-10-08

Lead Sponsor: Eastern Cooperative Oncology Group

Registration Number: NCT00469976

Carboplatin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Carboplatin
Drug: Gemcitabine Hydrochloride

First Posted Date: 2007-05-07

Last Posted Date: 2021-02-01

Lead Sponsor: University of Southampton

Target Recruit Count: 5

Registration Number: NCT00470249

Locations: 🇬🇧
Royal Bournemouth Hospital, Bournemouth, England, United Kingdom
🇬🇧
Portsmouth Oncology Centre at Saint Mary's Hospital, Portsmouth, England, United Kingdom
🇬🇧
Southampton General Hospital, Southampton, England, United Kingdom

Doxorubicin Hydrochloride Liposome and Carboplatin in Treating Patients With Recurrent, Stage III, or Stage IV Primary Endometrial Cancer

Phase 2

Terminated

Conditions: Endometrial Cancer

Interventions: Drug: carboplatin
Drug: pegylated liposomal doxorubicin hydrochloride

First Posted Date: 2007-05-07

Last Posted Date: 2014-08-22

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 9

Registration Number: NCT00470067

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors

Phase 2

Completed

Conditions: Childhood Extracranial Germ Cell Tumor
Childhood Malignant Ovarian Germ Cell Tumor
Childhood Malignant Testicular Germ Cell Tumor
Ovarian Yolk Sac Tumor
Recurrent Childhood Malignant Germ Cell Tumor
Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
Ovarian Embryonal Carcinoma
Recurrent Malignant Testicular Germ Cell Tumor
Ovarian Choriocarcinoma
Recurrent Ovarian Germ Cell Tumor

Interventions: Drug: Carboplatin
Biological: Filgrastim
Drug: Ifosfamide
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel

First Posted Date: 2007-04-27

Last Posted Date: 2018-08-29

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 20

Registration Number: NCT00467051

Locations: 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸
Palmetto Health Richland, Columbia, South Carolina, United States

and more 92 locations

Paclitaxel and Carboplatin Followed by Cisplatin and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer

Phase 2

Conditions: Cervical Cancer

First Posted Date: 2007-04-19

Last Posted Date: 2013-08-26

Lead Sponsor: University College London Hospitals

Target Recruit Count: 50

Registration Number: NCT00462397

Locations: 🇬🇧
Leicester Royal Infirmary, Leicester, England, United Kingdom
🇬🇧
Royal Marsden - London, London, England, United Kingdom
🇬🇧
University College of London Hospitals, London, England, United Kingdom